Nivolumab-related immune-related adverse events in advanced NSCLC predict therapeutic objective response - Rogado, J; Pacheco Barcia, V; Vera, B; Toquero, P; Mondejar, R; Ballesteros Garcia, A I; Donnay, O; Romero Laorden, N; Colomer Bosch, R; Sanchez-Torres, J M (Journal Of Thoracic Oncology, 2018)